BridgeBio reports second late-stage rare disease drug success, establishing new treatment potential for endocrine disorder ...
Crinetics Pharmaceuticals' stock has surged after FDA approval of Palsonify for acromegaly. Click here to read the latest ...
The number of medications in development to treat obesity continues to grow, and the drugs can offer health benefits for ...
The decision by the Canadian regulator is supported by the findings from the Phase III DESTINY-Breast06 study.
Pregnancy complications such as gestational diabetes mellitus (GDM), preeclampsia, and gestational hypertensive disorders are becoming increasingly ...
Philstar Life on MSN
EXPLAINER: What is latent autoimmune diabetes?
Sam Milby recently revealed his battle with latent autoimmune diabetes, which he said came as a surprise to him because he ...
Eruptive xanthoma is considered a rare disease with an incidence of 18 out of 100,000. It can only be seen in 10% of patients ...
The FDA has set a PDUFA target action date of March 29, 2026.
Viking Therapeutics, Inc. ("Viking") , a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that the ...
Climate change has lengthened the hot season in many parts of the U.S., which enhances the risk for workers. Schlader and ...
Significant increases in risk were linked to menopausal hormone therapy for all autoimmune diseases except Graves disease and hepatitis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback